SIOPEN brings together clinicians from across Europe and beyond to improve the outcomes for patients with neuroblastoma.
International collaboration is vital because neuroblastoma is uncommon. Collaboration ensures there are enough patients to do clinical studies. This allows us to learn more about the condition and improve treatments. SIOPEN runs a number of large clinical trials examining how best to treat neuroblastoma. In addition, it leads research into the biology of neuroblastoma to provide a better understanding of how the disease develops and how these different types respond to treatment. There are Speciality Committees which focus on specific areas such as biology, pathology, imaging techniques, molecular monitoring of response and surgery.